Europe may delay transparency

Share this article:

The push for clinical trial transparency may be delayed. Pharmalot reports that the European Medicines Agency is wading through more than 1,000 comments supporting the initiative and vociferous attacks from the industry and its backers who claim the initiative will threaten patient safety and corporate intellectual property. Threats to pack up and take jobs elsewhere have also accompanied industry concerns.

The EMA planned on having data out in the open by January 2104. It will decide in December if this date is still possible.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.